Gilead Sciences may perhaps, in the finish, be forced to supply a
lower price tag for its $94,500 hepatitis C drug. The biotechnology firm
could have no choice but to negotiate its personal discounts with CVS
Wellness and other drug advantage managers, say...
The biotechnology firm could have no choice but to negotiate its
personal discounts with CVS Wellness and other drug advantage managers,
say analysts, after rival drugmaker AbbVie announced the deal Monday to
block Gilead's pill Harvoni from a list of medicines covered by Express
Scripts Holding Co.
Express Scripts manages pharmacy positive
aspects for about 85 million individuals in the U.S., although CVS had
about 26 % of the pharmacy advantages marketplace in the U.S. final
year, behind Express Scripts, according to the U.S. Division of Labor.
Gilead truly want to be blocked from half of the U.S. population?" John
Kreger, an analyst at William Blair & Co., said in a phone
interview Monday. "They would be the most motivated to reduce a deal
Labels: Abbvie, CVS, Express Scripts, Gilead, price wars